Efficacy of osimertinib against EGFRvIII+ glioblastoma

Epidermal Growth Factor Receptor variant III (EGFRvIII) is an active mutant form of EGFR that drives tumor growth in a subset of glioblastoma (GBM). It occurs in over 20% of GBMs, making it a promising receptor for small molecule targeted therapy. We hypothesize that poor penetration of the blood-br...

Descripción completa

Detalles Bibliográficos
Autores principales: Chagoya, Gustavo, Kwatra, Shawn G., Nanni, Cory W., Roberts, Callie M., Phillips, Samantha M., Nullmeyergh, Sarah, Gilmore, Samuel P., Spasojevic, Ivan, Corcoran, David L., Young, Christopher C., Ballman, Karla V., Ramakrishna, Rohan, Cross, Darren A., Markert, James M., Lim, Michael, Gilbert, Mark R., Lesser, Glenn J., Kwatra, Madan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275784/
https://www.ncbi.nlm.nih.gov/pubmed/32547705
http://dx.doi.org/10.18632/oncotarget.27599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7275784/
https://www.ncbi.nlm.nih.gov/pubmed/32547705
http://dx.doi.org/10.18632/oncotarget.27599

Ejemplares similares